



Attorney Docket No. 5857

**RECEIVED**

DEC 20 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant(s): Jacques P. Dumas, et al.

Group Art Unit: 1624

Serial No: 09/636,519

Examiner: V. Balasubramanian

Filed: 08/10/2000


For: Substituted Pyridazines and Fused Pyridazines with Angiogenesis Inhibiting Activity

#6  
12/22/01  
MW

**CERTIFICATION OF MAILING UNDER 37 C.F.R. 1.8(a)**

I hereby certify that this correspondence and any papers referred to as attached are being deposited, on the date shown below, with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: December 10, 2001

  
Beatriz Alviz

**RESPONSE TO RESTRICTION REQUIREMENT**


**Assistant Commissioner for Patents**

**Washington, DC 20231**

Sir:

This is in response to the Office Action dated 10/10/01. In response to the restriction requirement, applicants elect the claims of restriction group II for further prosecution in this application. In response to the election or species requirement, applicants elect the compound of example 1, the structure of which is shown below.

Elected species:



Claims 7-12 read on the elected species.

Respectfully submitted,

William F. Gray  
Bayer Corporation  
400 Morgan Lane  
West Haven, CT 06516-4175

Reg. No. 31018

Phone: (203) 812-2712

Date: 10 December 2001